Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and Equipment
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fresenius Medical Care AG (FMS) Non-cash Items (2019 - 2025)

Historic Non-cash Items for Fresenius Medical Care AG (FMS) over the last 7 years, with Q2 2025 value amounting to $536.5 million.

  • Fresenius Medical Care AG's Non-cash Items rose 1778.73% to $536.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was $536.5 million, marking a year-over-year increase of 1778.73%. This contributed to the annual value of $480.9 million for FY2024, which is 927.34% up from last year.
  • According to the latest figures from Q2 2025, Fresenius Medical Care AG's Non-cash Items is $536.5 million, which was up 1778.73% from $454.4 million recorded in Q1 2025.
  • In the past 5 years, Fresenius Medical Care AG's Non-cash Items ranged from a high of $545.4 million in Q1 2024 and a low of $143.0 million during Q4 2021
  • For the 5-year period, Fresenius Medical Care AG's Non-cash Items averaged around $370.6 million, with its median value being $408.9 million (2023).
  • In the last 5 years, Fresenius Medical Care AG's Non-cash Items plummeted by 5183.36% in 2021 and then soared by 12831.29% in 2022.
  • Quarter analysis of 5 years shows Fresenius Medical Care AG's Non-cash Items stood at $143.0 million in 2021, then soared by 128.31% to $326.5 million in 2022, then soared by 34.79% to $440.1 million in 2023, then rose by 9.27% to $480.9 million in 2024, then grew by 11.58% to $536.5 million in 2025.
  • Its Non-cash Items was $536.5 million in Q2 2025, compared to $454.4 million in Q1 2025 and $480.9 million in Q4 2024.